Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analyses

Cancer Research

Volumn 69, Issue 9, 2009, Pages 4027-4035

  Ebi, Hiromichi ^a   Tomida, Shuta ^a   Takeuchi, Toshiyuki ^b   Arima, Chinatsu ^a   Sato, Takahiko ^a   Mitsudomi, Tetsuya ^c   Yatabe, Yasushi ^d   Osada, Hirotaka ^a,d   Takahashi, Takashi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Research Institute   (Japan)

^c Department of Thoracic Surgery   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; AMINO ACID; DNA; GLUCOSE; MAMMALIAN TARGET OF RAPAMYCIN; PHENOTHIAZINE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; RAPAMYCIN; RESVERATROL;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOINFORMATICS; CANCER CLASSIFICATION; CELL CYCLE PROGRESSION; CLINICAL STUDY; COMPUTER MODEL; CONTROLLED STUDY; DATA BASE; DEREGULATION; DNA DAMAGE; DOWN REGULATION; EXPERIMENTAL STUDY; FEMALE; FOOD AND DRUG ADMINISTRATION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; MALE; PRIORITY JOURNAL; PROGNOSIS; VALIDATION STUDY;

ADENOCARCINOMA; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; FURANS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; PYRIMIDINES; SIGNAL TRANSDUCTION; SIROLIMUS; TRANSCRIPTION FACTORS;

EID: 65949087244     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3403     Document Type: Article

References (36)

1. Takeuchi T, Tomida S, Yatabe Y, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol 2006; 24: 1679-88.
2. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002; 8: 816-24.
3. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006; 355: 570-80.
4. Tomida S, Koshikawa K, Yatabe Y, et al. Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene 2004; 23: 5360-70.
5. Lau SK, Boutros PC, Pintilie M, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 2007; 25: 5562-9.
6. Tomida S, Takeuchi T, Shimada Y, et al. Relapserelated molecular signature in lung adenocarcinoma identifies patients with dismal prognosis. J Clin Oncol. In press 2009, doi: 10.1200/JCO.2008.19.7053.
7. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis:a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102: 15545-50.
8. Lamb J, Crawford ED, Peck D, et al. The Connectivity Map:using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 1929-35.
9. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003; 33: 49-54.
10. Shedden K, Taylor JM, Enkemann SA, et al. Gene expression-based survival prediction in lung adenocarcinoma:a multi-site, blinded validation study. Nat Med 2008; 14: 822-7.
11. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998; 95: 14863-8.
12. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000; 103: 253-62.
13. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005; 37: 19-24.
14. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9-22.
15. Wei G, Twomey D, Lamb J, et al. Gene expressionbased chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006; 10: 331-42.
16. Knight ZA, Gonzalez B, Feldman ME, et al. A pharmacological map of the PI3-K family defines a role for p110a in insulin signaling. Cell 2006; 125: 733-47.
17. Fan QW, Knight ZA, Goldenberg DD, et al. A dual PI3kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006; 9: 341-9.
18. Lu Y, Lemon W, Liu PY, et al. A gene expression signature predicts survival of patients with stage I nonsmall cell lung cancer. PLoS Med 2006; 3: e467.
19. Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007; 356: 11-20.
20. Bianchi F, Nuciforo P, Vecchi M, et al. Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest 2007; 117: 3436-44.
21. Larsen JE, Pavey SJ, Passmore LH, Bowman RV, Hayward NK, Fong KM. Gene expression signature predicts recurrence in lung adenocarcinoma. Clin Cancer Res 2007; 13: 2946-54.
22. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439: 353-7.
23. Ji H, Ramsey MR, Hayes DN, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007; 448: 807-10.
24. Shah U, Sharpless NE, Hayes DN. LKB1 and lung cancer:more than the usual suspects. Cancer Res 2008; 68: 3562-5.
25. Roos S, Jansson N, Palmberg I, Saljo K, Powell TL, Jansson T. Mammalian target of rapamycin in the human placenta regulates leucine transport and is down-regulated in restricted fet al. growth. J Physiol 2007; 582: 449-59.
26. Kimball SR, Jefferson LS. Signaling pathways and molecular mechanisms through which branched-chain amino acids mediate translational control of protein synthesis. J Nutr 2006; 136: 227-31S.
27. Chen G, Gharib TG, Wang H, et al. Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A 2003; 100: 13537-42.
28. Conde E, Suarez-Gauthier A, Garcia-Garcia E, et al. Specific pattern of LKB1 and phospho-acetyl-CoA carboxylase protein immunostaining in human normal tissues and lung carcinomas. Hum Pathol 2007; 38: 1351-60.
29. Onozato R, Kosaka T, Achiwa H, et al. LKB1 gene mutations in Japanese lung cancer patients. Cancer Sci 2007; 98: 1747-51.
30. Balsara BR, Pei J, Mitsuuchi Y, et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004; 25: 2053-9.
31. Massion PP, Taflan PM, Shyr Y, et al. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med 2004; 170: 1088-94.
32. Tsurutani J, Fukuoka J, Tsurutani H, et al. Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in nonsmall-cell lung cancer tumors. J Clin Oncol 2006; 24: 306-14.
33. Gridelli C, Maione P, Rossi A. The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist 2008; 13: 139-47.
34. Baur JA, Sinclair DA. Therapeutic potential of resveratrol:the in vivo evidence. Nat Rev Drug Discov 2006; 5: 493-506.
35. Zhang L, Yu J, Pan H, et al. Small molecule regulators of autophagy identified by an image-based highthroughput screen. Proc Natl Acad Sci U S A 2007; 104: 19023-8.
36. Esumi H, Lu J, Kurashima Y, Hanaoka T. Antitumor activity of pyrvinium pamoate, 6- (dimethylamino) -2-[2- (2, 5-dimethyl-1-phenyl-1H-pyrrol-3-yl) ethenyl]-1- methyl-quinolinium pamoate salt, showing preferential cytotoxicity during glucose starvation. Cancer Sci 2004; 95: 685-90.